NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Breast Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
Globally, breast cancer is the second most common cancer after lung cancer....
....and the most common cancer for women. It is the second most common cause of death from cancer in women after lung cancer.
The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.
Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. Over the next six years Espicom forecasts that novel therapies including targeted monoclonal antibodies and small-molecul
Copyright©2010 PR Newswire.
All rights reserved